Progyny (NASDAQ: PGNY) insider transactions
In the twelve months to 10 November 2026, executives and directors of Progyny reported 31 open-market sales of 431,192 shares ($14.4m) and 1 open-market purchase of 79,500 shares ($1.9m), by 8 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 9 November 2026 | Schlanger David J | Executive Chairman | Option exercise, 10b5-1 plan | +161,208 | $0.91 | 399,670 | Form 4 |
| 9 November 2026 | Schlanger David J | Executive Chairman | Open-market sale, 10b5-1 plan | −161,208 | $35.73 | 238,462 | Form 4 |
| 9 November 2026 | Anevski Peter | Chief Executive Officer | Option exercise, 10b5-1 plan | +126,204 | $0.91 | 923,776 | Form 4 |
| 9 November 2026 | Anevski Peter | Chief Executive Officer | Open-market sale, 10b5-1 plan | −126,204 | $35.73 | 797,572 | Form 4 |
| 9 November 2026 | Anevski Peter | Chief Executive Officer | Open-market sale, 10b5-1 plan | −35,104 | $35.73 | 762,468 | Form 4 |
| 5 November 2026 | Schlanger David J | Executive Chairman | Option exercise, 10b5-1 plan | +3,400 | $0.91 | 241,862 | Form 4 |
| 5 November 2026 | Schlanger David J | Executive Chairman | Open-market sale, 10b5-1 plan | −3,400 | $35.22 | 238,462 | Form 4 |
| 5 November 2026 | Anevski Peter | Chief Executive Officer | Option exercise, 10b5-1 plan | +3,400 | $0.91 | 809,511 | Form 4 |
| 5 November 2026 | Anevski Peter | Chief Executive Officer | Open-market sale, 10b5-1 plan | −3,400 | $35.23 | 806,111 | Form 4 |
| 5 November 2026 | Anevski Peter | Chief Executive Officer | Open-market sale, 10b5-1 plan | −8,539 | $35.09 | 797,572 | Form 4 |
| 4 November 2026 | Livingston Mark S. | Chief Financial Officer | Open-market sale, 10b5-1 plan | −2,139 | $30.00 | 70,314 | Form 4 |
| 2 November 2026 | Swartz Allison | EVP, GC | Grant or award | +8,160 | — | 83,976 | Form 4 |
| 14 October 2026 | Cummings Melissa B | Chief Operating Officer | Shares withheld for tax, 10b5-1 plan | −1,559 | $27.39 | 68,375 | Form 4 |
| 14 October 2026 | Cummings Melissa B | Chief Operating Officer | Open-market sale, 10b5-1 plan | −1,879 | $28.00 | 66,496 | Form 4 |
| 23 September 2026 | Swartz Allison | EVP, GC | Open-market sale, 10b5-1 plan | −3,903 | $26.10 | 75,816 | Form 4 |
| 17 September 2026 | Clapp Geoffrey | Chief Product Officer | Shares withheld for tax | −819 | $27.38 | 59,009 | Form 4 |
| 10 September 2026 | Gordon Kevin K | Director | Option exercise | +22,000 | $13.00 | 28,792 | Form 4 |
| 10 September 2026 | Gordon Kevin K | Director | Shares withheld for tax | −10,500 | $27.24 | 18,292 | Form 4 |
| 10 September 2026 | Gordon Kevin K | Director | Open-market sale | −11,500 | $27.94 | 6,792 | Form 4 |
| 4 September 2026 | Livingston Mark S. | Chief Financial Officer | Shares withheld for tax | −479 | $26.61 | 72,453 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Progyny page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.